文献速递心脑血管急症重症综合管理与镇静镇痛

凝血酶原复合物与保守治疗在直接口服抗凝药相关脑出血中的比较

Prothrombin Complex Concentrate vs Conservative Management in ICH Associated With Direct Oral Anticoagulants.
PubMed 文献 · JAMA Netw Open · 2024-02-05
一句话结论在直接口服抗凝药相关脑出血患者中,凝血酶原复合物治疗与功能恢复、血肿扩大或死亡率改善均无显著关联。

该研究为基于人群的倾向评分加权回顾性队列研究,纳入2016年1月1日至2021年12月31日香港232例直接口服抗凝药相关脑出血患者,比较接受25-50 IU/kg凝血酶原复合物治疗与未接受止血治疗者的结局。凝血酶原复合物与神经功能恢复(aOR 0.62;95%CI 0.33-1.16;P=0.14)、90天死亡率(aOR 1.03;95%CI 0.70-1.53;P=0.88)、院内死亡率(aOR 1.11;95%CI 0.69-1.79;P=0.66)及血肿扩大(aOR 0.94;95%CI 0.38-2.31;P=0.90)均无显著关联。基线血肿体积较大、格拉斯哥昏迷评分较低及脑室出血与神经功能恢复几率降低相关,但与血肿扩大无关。作者认为需要进一步研究新型止血剂以及神经外科和辅助药物治疗,以确定直接口服抗凝药相关脑出血的最佳管理方案。

要点

  • 在232例直接口服抗凝药相关脑出血患者中,凝血酶原复合物(25-50 IU/kg)与保守治疗相比,神经功能恢复无显著改善(aOR 0.62;95%CI 0.33-1.16;P=0.14)。
  • 凝血酶原复合物与90天死亡率(aOR 1.03;95%CI 0.70-1.53;P=0.88)和院内死亡率(aOR 1.11;95%CI 0.69-1.79;P=0.66)均无显著关联。
  • 凝血酶原复合物与血肿扩大无显著关联(aOR 0.94;95%CI 0.38-2.31;P=0.90)。
  • 基线血肿体积较大、格拉斯哥昏迷评分较低及脑室出血与神经功能恢复几率降低相关,但与血肿扩大无关。
  • 作者认为需要进一步研究新型止血剂以及神经外科和辅助药物治疗,以确定直接口服抗凝药相关脑出血的最佳管理方案。

适用人群与场景

  • 2016年1月1日至2021年12月31日在香港发生直接口服抗凝药相关脑出血的患者。
  • 纳入232例,平均(SD)年龄77.2(9.3)岁,101例(44%)为女性。

处置流程与药物剂量

  • 凝血酶原复合物组接受25-50 IU/kg凝血酶原复合物治疗;对照组未接受止血剂治疗。

研究设计与关键结果

  • 研究类型:基于人群的倾向评分加权回顾性队列研究,纳入232例直接口服抗凝药相关脑出血患者,其中116例(50%)接受保守治疗,102例(44%)接受凝血酶原复合物治疗。
  • 主要终点:3个月时改良Rankin量表0-3分或恢复至基线功能状态,74例(31%)患者神经功能恢复良好;凝血酶原复合物与保守治疗相比无显著改善(aOR 0.62;95%CI 0.33-1.16;P=0.14)。
  • 次要终点:92例(39%)在90天内死亡;凝血酶原复合物与90天死亡率无显著关联(aOR 1.03;95%CI 0.70-1.53;P=0.88),与院内死亡率无显著关联(aOR 1.11;95%CI 0.69-1.79;P=0.66),与血肿扩大无显著关联(aOR 0.94;95%CI 0.38-2.31;P=0.90)。
  • 基线血肿体积中位数(IQR)为21.7 mL(3.6-66.1 mL)。
  • 基线血肿体积较大、格拉斯哥昏迷评分较低及脑室出血与神经功能恢复几率降低相关,但与血肿扩大无关。

证据类型、等级与局限

  • 证据类型:基于人群的倾向评分加权回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,需要进一步研究新型止血剂以及神经外科和辅助药物治疗,以确定直接口服抗凝药相关脑出血的最佳管理方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Intracerebral hemorrhage (ICH) associated with direct oral anticoagulant (DOAC) use carries extremely high morbidity and mortality. The clinical effectiveness of hemostatic therapy is unclear.

OBJECTIVE: To compare the clinical and radiological outcomes of DOAC-associated ICH treated with prothrombin complex concentrate (PCC) vs conservative management.

DESIGN, SETTING, AND PARTICIPANTS: In this population-based, propensity score-weighted retrospective cohort study, patients who developed DOAC-associated ICH from January 1, 2016, to December 31, 2021, in Hong Kong were identified. The outcomes of patients who received 25 to 50 IU/kg PCC with those who received no hemostatic agents were compared. Data were analyzed from May 1, 2022, to June 30, 2023.

MAIN OUTCOMES AND MEASURES: The primary outcome was modified Rankin scale of 0 to 3 or returning to baseline functional status at 3 months. Secondary outcomes were mortality at 90 days, in-hospital mortality, and hematoma expansion. Weighted logistic regression was performed to evaluate the association of PCC with study outcomes. In unweighted logistic regression models, factors associated with good neurological outcome and hematoma expansion in DOAC-associated ICH were identified.

RESULTS: A total of 232 patients with DOAC-associated ICH, with a mean (SD) age of 77.2 (9.3) years and 101 (44%) female patients, were included. Among these, 116 (50%) received conservative treatment and 102 (44%) received PCC. Overall, 74 patients (31%) patients had good neurological recovery and 92 (39%) died within 90 days. Median (IQR) baseline hematoma volume was 21.7 mL (3.6-66.1 mL). Compared with conservative management, PCC was not associated with improved neurological recovery (adjusted odds ratio [aOR], 0.62; 95% CI, 0.33-1.16; P = .14), mortality at 90 days (aOR, 1.03; 95% CI, 0.70-1.53; P = .88), in-hospital mortality (aOR, 1.11; 95% CI, 0.69-1.79; P = .66), or reduced hematoma expansion (aOR, 0.94; 95% CI, 0.38-2.31; P = .90). Higher baseline hematoma volume, lower Glasgow coma scale, and intraventricular hemorrhage were associated with lower odds of good neurological outcome but not hematoma expansion.

CONCLUSIONS AND RELEVANCE: In this cohort study, Chinese patients with DOAC-associated ICH had large baseline hematoma volumes and high rates of mortality and functional disability. PCC treatment was not associated with improved functional outcome, hematoma expansion, or mortality. Further studies on novel hemostatic agents as well as neurosurgical and adjunctive medical therapies are needed to identify the best management algorithm for DOAC-associated ICH.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Ip B, Pan S, Yuan Z, et al. Prothrombin Complex Concentrate vs Conservative Management in ICH Associated With Direct Oral Anticoagulants. JAMA Netw Open. 2024. PMID: 38319661. doi:10.1001/jamanetworkopen.2023.54916

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。